Citations

Clear

3042 citation(s) found for "Kumar, S".

Diagnosis and Treatment of Perioperative Anemia: A Society for Perioperative Assessment and Quality Improvement Collaborative Review
Kumar, Mandeep , Hepner, David L. , Grawe, Erin S., Keshock, Maureen , Khambaty, Maleka , Patel, Manish S. , Sweitzer, BobbieJean, Sweitzer, BobbieJean

Mayo Clinic

Anesthesiology | September 12, 2024 | Volume: 141 | Issue: 5 | Pages: 984-996

10.1097/aln.0000000000005111 | PMID 39264293 Get It

Adjuvant Gamma Knife Radiosurgery for Advanced Juvenile Nasopharyngeal Angiofibroma
Raheja, Amol, Sharma, Manish , Singh, Manmohan , Kale, Shashank Sharad, Sharma, Suresh C. , Sharma, Manish S., Agrawal, Deepak Kumar

Mayo Clinic

Neurology India | September 7, 2024 | Volume: 69 | Issue: 5 | Pages: 1438-1441

10.4103/0028-3886.329611 | PMID 34747837 Get It

Ibrutinib-induced spinal haematoma in a patient with marginal zone lymphoma
Roberson, Fazela, Yadav, Sumeet K. , Krishnamoorthy, Geetha , Yadav, Sumeet Kumar , Vojjala, Nikhil

Mayo Clinic

BMJ Case Reports | August 31, 2024 | Volume: 17 | Issue: 8 | Pages: e260598

10.1136/bcr-2024-260598 | PMID 39216882 Get It

Bleeding diathesis is an uncommon side effect of ibrutinib use and is seen in less than 5% of the population. We describe a case of an elderly woman with ibrutinib-induced spontaneous major extradural haematoma presenting as acute compressive myelopathy. She is a known case of splenic marginal zone lymphoma with multiple extramedullary relapses and presented to the emergency department with acute-onset low backache, followed by urinary retention. MRI revealed extradural haemorrhage. After possible evaluation, she was diagnosed with ibrutinib-induced extradural haematoma.
Efficacy and Safety of Interleukin-12/23 and Interleukin-23 Inhibitors for Ulcerative Colitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Jaber, Fouad , Alsakarneh, Saqr , Alsharaeh, Tala , Salahat, Ahmed-Jordan, Jaber, Mohammad, Gangwani, Manesh Kumar , Kilani, Yassine , Alsakarneh, Saqr G , Ayyad, Mohammed , Abboud, Yazan , Mohamed, Islam , Ali, Hassam , Farraye, Francis A. , Hashash, Jana G.

Mayo Clinic

American Journal of Therapeutics | August 30, 2024 | Volume: 32 | Issue: 1 | Pages: e17-e29

10.1097/mjt.0000000000001766 | PMID 39212744 Get It

Background: Targeting interleukin-23 (IL-23) represents a significant therapeutic avenue for treating ulcerative colitis (UC). Study Question: What are the effectiveness and safety of selective inhibitors targeting IL-23p19 and IL-12/23p40 in individuals with moderate-to-severe UC? Data Sources: MEDLINE, Embase, Scopus, and Cochrane databases. Study Design: A systematic search of MEDLINE, Embase, Scopus, and Cochrane databases till January 15, 2024, to identify randomized controlled trials comparing IL-23p19 and IL-12/23p40 inhibitors against placebo or active comparators in UC patients. The primary outcome was clinical remission, with secondary outcomes including clinical response, endoscopic remission, and safety profiles during induction and maintenance phases. Using a fixed-effect model, we pooled dichotomous data with risk ratio (RR) and 95% confidence interval (CI) for analysis. Results: In 5 trials involving 1120 patients with moderate to severe UC, targeting IL-23 showed significant superiority in inducing clinical remission [RR: 2.08, 95% CI, (1.66–2.61)], endoscopic remission [RR: 1.73, 95% CI, (1.39–2.16)], and histologic remission [RR: 1.88, 95% CI, (1.34–2.64)]. Additionally, individuals treated with IL-12/23p40 or IL-23p19 antagonists maintained clinical remission [RR: 1.85, 95% CI, (1.53–2.23)], endoscopic remission [RR: 2.03, 95% CI, (1.60–2.57)], and histologic remission [RR: 1.66, 95% CI, (1.11–2.48)]. Targeting IL-23 was linked with a reduced risk of any adverse events (AE) during both induction [RR: 0.94, 95% CI, (0.86–1.02)] and maintenance phases [RR: 0.93, 95% CI, (0.86–0.99)], any serious AE during the induction phase [RR: 0.53, 95% CI, (0.36–0.78)], and withdrawal due to AEs compared to patients receiving placebo during induction [RR: 0.24, 95% CI (0.14, 0.43)]. Conclusion: Targeting IL-23 demonstrates efficacy and safety for inducing and maintaining clinical and endoscopic remission in moderate-to-severe UC patients.
Stone heart syndrome: A curious case of digoxin toxicity and calcium infusion
Hussein, Guleid , Krastev, Peter, Mallari, Arvin Junn P, Labban, Mohamad El , Yadav, Sumeet Kumar, Warsame, Mohamed , Zoesch, Greta, Trnka, John, Jain, Shika M., Khan, Syed Anjum , Surani, Salim , Hassan, Mohamed Sayed , Vojjala, Nikhil , Jain, Shika M , Surani, Salim

Mayo Clinic

Clinical Case Reports | August 30, 2024 | Volume: 12 | Issue: 9 | Pages: No page available

10.1002/ccr3.9376 | PMID 39219774 Get It

Key Clinical MessageStone heart syndrome has a complex interaction with digoxin toxicity, where, theoretically, the administration of intravenous calcium can worsen a patient's condition. Research on this subject is conflicting, so it is imperative to approach it cautiously.
Prognostic impact of cytogenetic abnormalities detected by FISH in AL amyloidosis with daratumumab-based frontline therapy
Zanwar, Saurabh , Hegenbart, Ute , Bhutani, Divaya , Gertz, Morie A. , Kumar, Shaji , Patwari, Anannya , Cowan, Andrew J., Chen, GuiZhen, Milani, Paolo , Bodanapu, Geethika , Lentzsch, Suzanne , Chakraborty, Rajshekhar , Hegenbart, Ute , Gertz, Morie A , Dispenzieri, Angela , Kumar, Shaji K , Chen, GuiZhen , Palladini, Giovanni , Sanchorawala, Vaishali , Bodanapu, Geethika , Muchtar, E , Milani, Paolo , Bhutani, Divaya , Chakraborty, Rajshekhar , Dispenzieri, Angela , D’Souza, Anita , Palladini, Giovanni , Schönland, Stefan , Muchtar, Eli

Mayo Clinic

Blood | August 28, 2024 | Volume: 144 | Issue: 25 | Pages: 2613-2624

10.1182/blood.2024025899 | PMID 39197073 Get It

Abstract We performed an international retrospective study on 283 patients with light chain (AL) amyloidosis to investigate the prognostic impact of cytogenetic abnormalities by fluorescence in situ hybridization, when treated with frontline daratumumab–based therapy. The cytogenetic subgroups of interest were t(11;14), gain/amp(1q) (hereafter, +1q), hyperdiploidy, deletion(13q), del(17p), and myeloma high-risk (HR) translocations (t[4;14], t[14;16], or t[14;20]). The end points of interest were rate of hematologic complete response (heme-CR), very good partial response (VGPR) or better, and hematologic event-free survival (heme-EFS). The incidence of abnormalities was as follows: t(11;14), 53.4%; deletion (13q), 28.9%; +1q, 22.3%; hyperdiploidy, 19.4%; HR translocations, 6.6%; and deletion(17p), 4.5%. The heme-CR rate by cytogenetic subgroups were as follows: t(11;14) vs no t(11;14), 45.2% vs 41.8% (P=0.597); del(13q) vs no del(13q), 46.8% vs 42.8% (P=0.594); +1q vs no +1q, 30.2% vs 47.9% (P=0.022); hyperdiploidy vs no hyperdiploidy, 39.5% vs 44.9% (P=0.541); HR translocations vs none, 45.5% vs 43.1% (P=0.877); and del(17p) vs no del(17p), 50.0% vs 42.9% (P=0.658), respectively. Similarly, +1q was the only subgroup with a significantly lower VGPR or better rate (64.2% vs 79.0%; P=0.033). At a median follow-up of 19.8 months, the median heme-EFS was 49.6 months (95% CI, 24.7-not reached [NR]), and the 2-year overall survival (OS) was 80.98% (95% CI, 75.6-85.4). The presence of +1q was significantly associated with worse heme-EFS on multivariate analysis (HR 2.06, 95% CI, 1.14-3.71; P=0.017). Notably, there was no adverse prognostic impact of t(11;14) on heme-EFS or OS. In conclusion, +1q is associated with worse outcome in the daratumumab-era. Clinical trials testing novel frontline immunotherapies should be enriched in +1q to further improve outcomes in this subgroup.
CSF-venous fistulas associated with traumatic spinal pseudomeningoceles
Madhavan, Ajay A. , Cutsforth‐Gregory, Jeremy K. , Kumar, Neeraj , Garza, Ivan , Whealy, Mark , Brinjikji, Waleed , Whealy, Mark A , Madhavan, Ajay A , Kissoon, Narayan

Mayo Clinic

Interventional Neuroradiology | August 27, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/15910199241276575 | PMID 39191383 Get It

CSF-venous fistulas (CVFs) are a common cause of spontaneous intracranial hypotension. These fistulas usually occur without any preceding major trauma, surgery, or other iatrogenic cause. Occasionally, patients have a history of minor trauma, though such cases are usually still considered spontaneous. Little is known about predisposing factors that cause patients to develop spontaneous CVFs. Most patients with CVFs have multiple meningeal diverticula on spine imaging, and fistulas usually arise in association with a diverticulum. In the vast majority of cases, the culprit diverticulum from which the CVF arises is atraumatic in origin, presumably on the spectrum of normal variation in spinal anatomy. Here, we present two cases of CVFs that arose in association with posttraumatic pseudomeningoceles. To our knowledge, this phenomenon has not yet been reported, and it potentially represents a novel etiology for CVFs that furthers understanding of their pathogenesis.
CREBBP histone acetyltransferase domain mutations predict response to mTOR inhibition in relapsed/refractory follicular lymphoma
Kumar, Emil , Korfi, Koorosh , Close, Karina , Leukam, Michael , Ansell, Stephen M. , Scott, Jessica, Clear, Andrew , Siebert, R., Peck, Barrie , Calaminici, Maria , Smith, Sonali M. , Novak, Anne J. , Kumar, Emil Arjun , Ansell, Stephen M , Fitzgibbon, Jude , Okosun, Jessica , Bewicke‐Copley, Findlay , Heward, James A. , Witzig, Thomas E. , Scott, Jessica, Efeyan, Alejo , Green, Michael Richard , Siebert, Reiner, Wang, Jun , Fitzgibbon, Jude

Mayo Clinic

British Journal of Haematology | August 27, 2024 | Volume: 205 | Issue: 5 | Pages: 1804-1809

10.1111/bjh.19671 | PMID 39188028 Get It

SummaryDespite the clinical and molecular heterogeneity of follicular lymphoma (FL), there remains a lack of biomarker‐directed therapeutic approaches in routine clinical practice, with the notable exception of the EZH2 inhibitor tazemetostat in EZH2‐mutant FL. Here we examined whether gene mutation status predicts response to clinical mTOR inhibitors (mTORi) in FL, by performing targeted mutational profiling of biopsies from 21 relapsed/refractory FL patients treated with mTORi everolimus or temsirolimus within clinical trials. We observed an enrichment of mutations within the catalytic histone acetyltransferase (HAT) domain of CREBBP in mTORi‐responders, and describe distinct transcriptional characteristics and co‐occurring mutations of FL harbouring these mutations; reinforcing the growing appreciation of CREBBPHAT mutation as a key biological determinant and its promise as a therapeutic biomarker in FL.
Inflammation, physical activity, and disease-free survival in stage III colon cancer: Cancer and Leukemia Group B–Southwest Oncology Group 80702 (Alliance)
Brown, Justin C. , Shi, Qian , Couture, Félix , Kuebler, Philip , Kumar, Pankaj , Tan, Benjamin , Krishnamurthi, Smitha , Chang, Victor T. , Goldberg, Richard M. , Shields, Anthony F. , Meyerhardt, Jeffrey A. , Brown, Justin C. , Kuebler, J. Philip , Shi, Qian , Chang, Victor T-S , Shields, Anthony F , Brown, Justin C , Meyerhardt, Jeffrey A , Ma, Chao , Goldberg, Richard M. , O’Reilly, Eileen M. , Brown, Justin C.

Mayo Clinic

JNCI: Journal of the National Cancer Institute | August 24, 2024 | Volume: 116 | Issue: 12 | Pages: 2032-2039

10.1093/jnci/djae203 | PMID 39180477 Get It

Abstract Background Inflammation and insufficient physical inactivity contribute to individual-level risk of disease recurrence and death in stage III colon cancer. The extent to which increased inflammatory risk can be offset by sufficient physical activity remains unknown. Methods This cohort study was nested within the Cancer and Leukemia Group B (now part of the Alliance for Clinical Trials in Oncology) and Southwest Oncology Group randomized trial. Inflammatory burden was quantified by high-sensitivity C-reactive protein, interleukin-6, and soluble tumor necrosis factor-α receptor 2 after recovery from tumor resection. Physical activity was measured during and after postoperative chemotherapy. The primary endpoint was disease-free survival. Results The 3-year disease-free survival rate was 88.4% among patients with low inflammation and sufficient physical activity (referent group for all comparisons), 84.9% with low inflammation and insufficient physical activity (absolute risk difference = −3.5 percentage points, 95% confidence interval [CI] = −11.3 to 4.3; P = .38), 78.0% with intermediate inflammation and insufficient physical activity (absolute risk difference = −10.4 percentage points, 95% CI = −17.4 to −3.3; P = .007), and 79.7% with high inflammation and insufficient physical activity (absolute risk difference = −8.7 percentage points, 95% CI = −15.7 to −1.6; P = .022). In contrast, the 3-year disease-free survival rate was 87.3% among patients with intermediate inflammation and sufficient physical activity (absolute risk difference = −1.1 percentage points, 95% CI = −7.5 to 5.3; P = .74) and 84.4% with high inflammation and sufficient physical activity (absolute risk difference = −4.0 percentage points, 95% CI = −12.3 to 4.3; P = .34). Conclusion In this observational study of stage III colon cancer patients, physical activity was associated with improved disease-free survival despite high inflammation. Patients with intermediate or high inflammation who were physically active had disease-free survival rates that were not statistically significantly different from those with low inflammation.
In-hospital Outcomes of early Versus Late Transcatheter Closure of Patent Ductus Arteriosus in Preterm Infants
Elsisy, Mohamed, Stephens, Elizabeth H. , Sreeniva, Gayathri, Nicholson, George T. , Gupta, Arpit Kumar

Mayo Clinic

No container title available | August 22, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-4783772/v1 Get It

Abstract Background Transcatheter closure of patent ductus arteriosus (PDA) in small, premature infants is increasingly performed in the contemporary practice. Data regarding optimal timing of PDA closure are scarce. We therefore decided to compare morbidity and mortality of early and late device closure in preterm infants. Methods Hospitalizations of 166,583 newborn infants diagnosed with PDA were identified from the Kids’ Inpatient Database (KID) in 2009, 2012, 2016, and 2019. Of these, 299 preterm infants (gestational age (GA) ≤32 weeks, birth weight <1500 grams) underwent percutaneous PDA closure. Characteristics and peri-procedural outcomes were compared between early (≤ 30 days) (n=120) and late PDA closure (>30 days) (n=179). Results Mean age (±standard deviation) for early PDA closure was 18.6 days ± 7 and 67.3 days ± 36.5 in late PDA closure. Co-morbidities including respiratory distress syndrome/bronchopulmonary dysplasia, heart failure and pulmonary hypertension were comparable between the two groups. There was no difference in mortality or referral for surgical ligation between early and late closure. Post-procedural vascular complications were low, but higher in patients with early PDA closure (3.3% vs 0%; p=0.025). Length of hospital stay was longer in late PDA closure group (121.1 days ± 51.7 vs 81.5 days ± 48.8; p=<0.01). Conclusion Preterm or very low birth weight infants may benefit from early percutaneous PDA closure as it is associated with a shorter hospital LOS. There was no difference in in-hospital mortality or major periprocedural complications between early and late PDA closure, except vascular complications that were higher with early PDA closure.